People · Operator
Named in public records as an officer, director or promoter · active 2011–2019 · Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Boragen, Inc. | — | Other | Series B | $43.0M | $32.1M | 2017 |
| Abide Therapeutics, Inc. | — | Pharmaceuticals | Seed | $2.2M | $83.7M | 2011 |
Paul Schimmel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Schimmel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kristina Burow | 1 | 16 |
| Joel Marcus | 1 | 9 |
| John Clarke | 1 | 8 |
| Alan Ezekowitz | 1 | 4 |
| Roger Kemble | 1 | 4 |
| JULIE GRANT | 1 | 3 |
| John Dombrosky | 1 | 3 |
| Tracy Jackson | 1 | 2 |
| Peter Farina | 1 | 2 |
| Benjamine Cravatt | 1 | 1 |
| Esther Van Den Boom | 1 | 1 |
| Raj Kaul | 1 | 1 |
| Rich Gianni | 1 | 1 |
| Stephen Benkovic | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.